1
|
Rippe C, Erlanson-Albertsson C. Identification of Enterostatin and the Relation between Lipase and Colipase in Various Species. Nutr Neurosci 2016; 1:111-7. [PMID: 27406016 DOI: 10.1080/1028415x.1998.11747220] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Enterostatin, the N-terminal activation peptide of pancreatic procolipase, has been identified in three different forms in rat: VPDPR (Val-Pro-Asp-Pro-Arg), APGPR (Ala-Pro-Gly-Pro-Arg) and VPGPR (Val-Pro-Gly-Pro-Arg). We investigated the possibility for a species to have several isoforms of enterostatin. Pancreas was purified from four different species (rat, mouse, cat and pig) and the enterostatin sequences were identified. At the same time, the activities of pancreatic lipase and colipase were measured. In rat and mouse pancreas APGPR was the only form of enterostatin identified. The colipase activity was 188 ± 25 U/mg protein in rat and 189 ± 16 U/mg in mouse and the lipase activity 354 ± 33 U/mg and 292 ± 19 U/mg respectively. Rat and mouse had a colipase/lipase ratio close to 0.5. In pancreas from cat and pig we only detected the form VPDPR (Val-Pro-Asp-Pro-Arg). We found the colipase activity in cat to be 493 ± 92 U/mg, while the lipase activity was three times lower, 167 ± 18 U/mg. Pig pancreas concentrations of colipase was 110 ± 8 U/mg and of lipase 38 ± 5 U/mg. In both cat and pig the colipase/lipase ratio was close to 3. This suggests that colipase might have an additional role than to restore the activity of lipase. Our hypothesis is that an overproduction of colipase and hence also enterostatin is involved in the regulation of fat metabolism.
Collapse
Affiliation(s)
- C Rippe
- a Department of Cell and Molecular Biology, Section for Molecular Signaling , University of Lund , PO Box 94, S-221 00 Lund , Sweden
| | - C Erlanson-Albertsson
- a Department of Cell and Molecular Biology, Section for Molecular Signaling , University of Lund , PO Box 94, S-221 00 Lund , Sweden
| |
Collapse
|
2
|
Lindqvist A, Berger K, Erlanson-Albertsson C. Enterostatin up-regulates the expression of the beta-subunit of F(1)F(o)-ATPase in the plasma membrane of INS-1 cells. Nutr Neurosci 2009; 11:55-60. [PMID: 18510804 DOI: 10.1179/147683008x301397] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Exposure to high-fat diet easily promotes overeating while at the same time disrupting insulin secretion and islet function. Enterostatin is a peptide which is secreted from the pancreas in response to high-fat feeding and has been shown to inhibit fat intake as well as insulin secretion in experimental animal models. Until recently, there was no known receptor for enterostatin. In 2002, Berger and co-workers found enterostatin to target the beta-subunit of the F(1)-ATPase in rat brain membranes as well as in a clonal beta-cell line (INS-1). In this study, we found the beta-subunit of F(1)-ATPase to be ectopically expressed in the plasma membrane of INS-1 cells using both immunohistochemistry and Western blotting. Incubation with enterostatin for 60 min resulted in a 3.5-fold increase of the protein expression of the beta-subunit of F(1)-ATPase in the plasma membrane. Furthermore, we found ATP to be able to displace the binding of enterostatin to purified bovine F(1)-ATPase. This reported targeting of enterostatin to the beta-subunit of F(1)-ATPase in insulin cells may provide a link between high-fat intake and islet function.
Collapse
|
3
|
Rippe C, Erlanson-Albertsson C, Lindqvist A. Consequences of metabolic challenges on hypothalamic colipase and PLRP2 mRNA in rats. Brain Res 2007; 1185:152-7. [PMID: 17936733 DOI: 10.1016/j.brainres.2007.09.022] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2007] [Revised: 09/04/2007] [Accepted: 09/12/2007] [Indexed: 01/09/2023]
Abstract
The hypothalamus is the main appetite-regulating center in the brain receiving peripheral signals regarding the metabolic status of the body. Pancreatic procolipase has recently been identified in rat hypothalamus. Procolipase is known mainly for its actions in the intestine where it is cleaved to colipase, an enzyme required for the maintenance of pancreatic lipase activity, and enterostatin, a peptide involved in appetite regulation through the gut-brain axis. Colipase is able to increase the activity of pancreatic lipase-related protein-2 (PLRP2), a lipase also expressed in extra-pancreatic tissues. This study was performed to elucidate if PLRP2, in addition to colipase, is expressed in the hypothalamus and if the mRNAs of colipase and PLRP2 respond to metabolic challenges such as fasting, high-fat feeding or feeding sugar solutions. RNA from rat hypothalamus was extracted and subjected to RT-PCR. For quantitative mRNA analysis of hypothalamic tissue from the different metabolic situations real-time RT-PCR was used. We found PLRP2 and colipase mRNA to be expressed in the hypothalamus. An overnight fast resulted in down-regulated colipase (3-fold) and PLRP2 (7-fold) mRNA compared to freely fed rats. Conversely, high-fat feeding resulted in up-regulated colipase and PLRP2 mRNA (1.3-fold and 1.8-fold, respectively) compared to standard chow-fed rats. A similar up-regulation in mRNA expression was observed after offering sugar solutions. In conclusion, PLRP2 mRNA is expressed in the rat hypothalamus and both procolipase and PLRP-2 mRNA are down-regulated during fasting and up-regulated during conditions of metabolic excess, suggesting an involvement in signaling energy availability.
Collapse
Affiliation(s)
- Catarina Rippe
- Department of Experimental Medical Science, BMC, B11, 221 84 Lund, Sweden
| | | | | |
Collapse
|
4
|
Ohinata K, Sonoda S, Shimano T, Yoshikawa M. Enterostatin (APGPR) enhances memory consolidation in mice. Peptides 2007; 28:719-21. [PMID: 17175068 DOI: 10.1016/j.peptides.2006.11.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/21/2006] [Revised: 11/06/2006] [Accepted: 11/07/2006] [Indexed: 11/23/2022]
Abstract
Enterostatin (APGPR) is a pentapeptide released from its precursor protein, procolipase. We found for the first time that enterostatin has memory-enhancing activity. Enterostatin enhanced memory consolidation after central or oral administration at a dose of 10 nmol/mouse or 300 mg/kg, respectively, in a step-through type passive avoidance test in mice. The memory-enhancing activity of enterostatin was inhibited by pretreatment with lorglumide, an antagonist for cholecystokinin 1 (CCK1) receptor. However, enterostatin had no affinity for CCK receptors. These results suggest that enterostatin improves memory retention through CCK release.
Collapse
Affiliation(s)
- Kousaku Ohinata
- Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Gokasho Uji, Kyoto 611-0011, Japan
| | | | | | | |
Collapse
|
5
|
Lin L, York DA. Amygdala enterostatin induces c-Fos expression in regions of hypothalamus that innervate the PVN. Brain Res 2004; 1020:147-53. [PMID: 15312796 DOI: 10.1016/j.brainres.2004.06.029] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/15/2004] [Indexed: 11/19/2022]
Abstract
Enterostatin selectively inhibits the intake of the dietary fat after both central and peripheral administration. Our previous studies have shown that a central site of action is the central nucleus of amygdala. Serotonergic agonists administered into the paraventricular nucleus (PVN) inhibit fat intake and serotonergic antagonists block the feeding suppression induced by amygdala enterostatin, suggesting that there are functional connections between the PVN and amygdala that affect the feeding response to enterostatin. Our purpose was to identify the anatomic and functional projections from the amygdala to the PVN and hypothalamic area that are responsive to enterostatin, by using a retrograde tracer fluorogold (FG) and c-Fos expression. Rats were injected with fluorogold unilaterally into the PVN and a chronic amygdala cannula was implanted ipsilaterally. After 10 days recovery, rats were injected with either enterostatin (0.1 nmol) or saline vehicle (0.1 microl) into the amygdala and sacrificed 2 h later by cardiac perfusion under anesthesia. The brains were subjected to dual immunohistochemistry to visualize both FG and c-Fos-positive cells. FG/c-Fos double-labeled cells were found in forebrain regions including the PVN, amygdala, lateral hypothalamus (LH), ventral medial hypothalamus (VMH) and arcuate nucleus (ARC). The data provides the first anatomical evidence that enterostatin activates amygdala neurons that have functional and anatomic projections directly to the PVN and also activates neurons in the arcuate, LH and VMH, which innervate the PVN.
Collapse
Affiliation(s)
- Ling Lin
- Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, Louisiana 70808, USA.
| | | |
Collapse
|
6
|
Inui A, Asakawa A, Bowers CY, Mantovani G, Laviano A, Meguid MM, Fujimiya M. Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J 2004; 18:439-56. [PMID: 15003990 DOI: 10.1096/fj.03-0641rev] [Citation(s) in RCA: 264] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Recent progress in the field of energy homeostasis was triggered by the discovery of adipocyte hormone leptin and revealed a complex regulatory neuroendocrine network. A late addition is the novel stomach hormone ghrelin, which is an endogenous agonist at the growth hormone secretagogne receptor and is the motilin-related family of regulatory peptides. In addition to its ability to stimulate GH secretion and gastric motility, ghrelin stimulates appetite and induces a positive energy balance leading to body weight gain. Leptin and ghrelin are complementary, yet antagonistic, signals reflecting acute and chronic changes in energy balance, the effects of which are mediated by hypothalamic neuropeptides such as neuropeptide Y and agouti-related peptide. Endocrine and vagal afferent pathways are involved in these actions of ghrelin and leptin. Ghrelin is a novel neuroendocrine signal possessing a wide spectrum of biological activities that illustrates the importance of the stomach in providing input into the brain. Defective ghrelin signaling from the stomach could contribute to abnormalities in energy balance, growth, and associated gastrointestinal and neuroendocrine functions.
Collapse
Affiliation(s)
- Akio Inui
- Division of Diabetes, Digestive and Kidney Diseases, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
| | | | | | | | | | | | | |
Collapse
|
7
|
Lin L, Thomas SR, Kilroy G, Schwartz GJ, York DA. Enterostatin inhibition of dietary fat intake is dependent on CCK-A receptors. Am J Physiol Regul Integr Comp Physiol 2003; 285:R321-8. [PMID: 12855414 DOI: 10.1152/ajpregu.00147.2003] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Enterostatin, a pentapeptide released from the exocrine pancreas and gastrointestinal tract, selectively inhibits fat intake through activation of an afferent vagal signaling pathway. This study investigated if the effects of enterostatin were mediated through a CCK-dependent pathway. The series of in vivo and in vitro experiments included studies of 1) the feeding effect of peripheral enterostatin on Otsuka Long Evans Tokushima Fatty (OLETF) rats lacking CCK-A receptors, 2) the effect of CCK-8S on the intake of a two-choice high-fat (HF)/low-fat (LF) diet, 3) the effects of peripheral or central injection of the CCK-A receptor antagonist lorglumide on the feeding inhibition induced by either central or peripheral enterostatin, and 4) the ability of enterostatin to displace CCK binding in a 3T3 cell line expressing CCK-A receptor gene and in rat brain sections. The results showed that OLTEF rats did not respond to enterostatin (300 microg/kg ip) in contrast to the 23% reduction in intake of HF diet in Long Evans Tokushima Otsuka (LETO) control rats. CCK (1 microg/kg ip) decreased the intake of the HF diet in a two-choice diet regime with a compensatory increase in intake of the LF diet. Peripheral injection of lorglumide (300 microg/kg) blocked the feeding inhibition induced by either near-celiac arterial or intracerebroventricular enterostatin, whereas intracerebroventricular lorglumide (5 nmol icv) only blocked the response to intracerebroventricular enterostatin but not to arterial enterostatin. Enterostatin did not bind on CCK-A receptors because neither enterostatin nor its analogs VPDPR and beta-casomorphin displaced [3H]L-364,718 from CCK-A receptors expressed in 3T3 cells or the binding of 125I-CCK-8S from rat brain sections. The data suggest that both the peripheral and central responses to enterostatin are mediated through or dependent on peripheral and central CCK-A receptors.
Collapse
Affiliation(s)
- Ling Lin
- Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA.
| | | | | | | | | |
Collapse
|
8
|
Mei J, Sörhede-Winzell M, Erlanson-Albertsson C. Plasma enterostatin: identification and release in rats in response to a meal. OBESITY RESEARCH 2002; 10:688-94. [PMID: 12105292 DOI: 10.1038/oby.2002.93] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVE To discover a possible absorption and/or secretion of enterostatin into the circulating blood, as well as to compare the levels of circulating enterostatin after high-fat feeding and low-fat feeding. RESEARCH METHODS AND PROCEDURES Using a specific enzyme-linked immunosorbent assay, plasma enterostatin levels were determined after feeding a high-fat, a high-fat/-sucrose, or a low-fat meal to Sprague-Dawley rats deprived of food overnight. RESULTS The enterostatin levels were increased by all diets; the response to the high-fat and the high-fat/-sucrose meals was greater in magnitude and duration than that to the low-fat meal. In addition, enterostatin levels correlated with the intake of dietary fat. Plasma enterostatin levels after high-fat feeding were found to be similar to those after intravenous administration of exogenous enterostatin known to inhibit high-fat food intake. Gel chromatography of pooled postprandial plasma extracts followed by high-performance liquid chromatography analysis showed that plasma enterostatin was identical to synthetic enterostatin. Affinity cross-linking of plasma proteins with 125I-enterostatin on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by autoradiography, revealed a single band with a molecular weight of about 66 kDa, indicating the presence of a potential enterostatin-binding protein in plasma. DISCUSSION The measurements of plasma enterostatin may be a sensitive indicator for the measurement of fat intake.
Collapse
Affiliation(s)
- Jie Mei
- Department of Cell and Molecular Biology, University of Lund, Lund, Sweden
| | | | | |
Collapse
|
9
|
Abstract
Esta revisão apresenta informações a respeito de substâncias fisiológicas que afetam a homeostase energética. Os autores fizeram uma extensa revisão em relação aos mecanismos fisiológicos que modulam o balanço energético quando administrados central ou perifericamente (por exemplo, nutrientes, monoaminas e peptídeos).
Collapse
|
10
|
Berger K, Sivars U, Winzell MS, Johansson P, Hellman U, Rippe C, Erlanson-Albertsson C. Mitochondrial ATP synthase--a possible target protein in the regulation of energy metabolism in vitro and in vivo. Nutr Neurosci 2002; 5:201-10. [PMID: 12041876 DOI: 10.1080/10284150290008604] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
The increasing prevalence of obesity in the Western world has stimulated an intense search for mechanisms regulating food intake and energy balance. A number of appetite-regulating peptides have been identified, their receptors cloned and the intracellular events characterized. One possible energy-dissipating mechanism is the mitochondrial uncoupling of ATP-synthesis from respiratory chain oxidation through uncoupling proteins, whereby energy derived from food could be dissipated as heat, instead of stored as ATP. The exact role of the uncoupling proteins in energy balance is, however, uncertain. We show here that mitochondrial F1F0-ATP synthase itself is a target protein for an anorectic peptide, enterostatin, demonstrated both after affinity purification of rat brain membranes and through a direct physical interaction between enterostatin and purified F1-ATP synthase. In insulinoma cells (INS-1) enterostatin was found to target F1F0-ATP synthase, causing an inhibition of ATP production, an increased thermogenesis and increased oxygen consumption. The experiments suggest a role of mitochondrial F1F0-ATP synthase in the suppressed insulin secretion induced by enterostatin. It could be speculated that this targeting mechanism is involved in the decreased energy efficiency following enterostatin treatment in rat.
Collapse
Affiliation(s)
- Karin Berger
- Department of Cell and Molecular Biology, Biomedical Center, University of Lund, Sweden.
| | | | | | | | | | | | | |
Collapse
|
11
|
Abstract
The current experiments were designed to compare the feeding response to enterostatin and beta-casomorphin(1-7) injected intragastrically. Sprague-Dawley rats with a gastric cannula were allowed to chose from high-fat diet (HF) or low-fat diet (LF) in separate jars. Enterostatin injected intragastrically into overnight fasted rats caused a U-shaped dose-dependent reduction in the intake of the HF diet for the first two hours after infusion but had no effect on the LF intake. beta-Casomorphin(1-7) stimulated the intake of the HF diet but had no effect on the LF diet. Finally, beta-casomorphin(1-7) blocked the inhibitory effect of enterostatin on HF intake in fasted rats.
Collapse
Affiliation(s)
- C L White
- Pennington Biomedical Research Center, Louisiana State University, 6400 Perkins Road, Baton Rouge, LA 70808, USA
| | | | | |
Collapse
|
12
|
Abstract
Food intake is a regulated system. Afferent signals provide information to the central nervous system, which is the centre for the control of satiety or food seeking. Such signals can begin even before food is ingested through visual, auditory and olfactory stimuli. One of the recent interesting findings is the demonstration that there are selective fatty acid taste receptors on the tongue of rodents. The suppression of food intake by essential fatty acids infused into the stomach and the suppression of electrical signals in taste buds reflect activation of a K rectifier channel (K 1.5). In animals that become fat eating a high-fat diet the suppression of this current by linoleic acid is less than that in animals that are resistant to obesity induced by dietary fat. Inhibition of fatty acid oxidation with either mercaptoacetate (which blocks acetyl-CoA dehydrogenase) or methylpalmoxirate will increase food intake. When animals have a choice of food, mercaptoacetate stimulates the intake of protein and carbohydrate, but not fat. Afferent gut signals also signal satiety. The first of these gut signals to be identified was cholecystokinin (CCK). When CCK acts on CCK-A receptors in the gastrointestinal tract, food intake is suppressed. These signals are transmitted by the vagus nerve to the nucleus tractus solitarius and thence to higher centres including the lateral parabrachial nucleus, amygdala, and other sites. Rats that lack the CCK-A receptor become obese, but transgenic mice lacking CCK-A receptors do not become obese. CCK inhibits food intake in human subjects. Enterostatin, the pentapeptide produced when pancreatic colipase is cleaved in the gut, has been shown to reduce food intake. This peptide differs in its action from CCK by selectively reducing fat intake. Enterostatin reduces hunger ratings in human subjects. Bombesin and its human analogue, gastrin inhibitory peptide (also gastrin-insulin peptide), reduce food intake in obese and lean subjects. Animals lacking bombesin-3 receptor become obese, suggesting that this peptide may also be important. Circulating glucose concentrations show a dip before the onset of most meals in human subjects and rodents. When the glucose dip is prevented, the next meal is delayed. The dip in glucose is preceded by a rise in insulin, and stimulating insulin release will decrease circulating glucose and lead to food intake. Pyruvate and lactate inhibit food intake differently in animals that become obese compared with lean animals. Leptin released from fat cells is an important peripheral signal from fat stores which modulates food intake. Leptin deficiency or leptin receptor defects produce massive obesity. This peptide signals a variety of central mechanisms by acting on receptors in the arcuate nucleus and hypothalamus. Pancreatic hormones including glucagon, amylin and pancreatic polypeptide reduce food intake. Four pituitary peptides also modify food intake. Vasopressin decreases feeding. In contrast, injections of desacetyl melanocyte-stimulating hormone, growth hormone and prolactin are associated with increased food intake. Finally, there are a group of miscellaneous peptides that modulate feeding. beta-Casomorphin, a heptapeptide produced during the hydrolysis of casein, stimulates food intake in experimental animals. In contrast, the other peptides in this group, including calcitonin, apolipoprotein A-IV, the cyclized form of histidyl-proline, several cytokines and thyrotropin-releasing hormone, all decrease food intake. Many of these peptides act on gastrointestinal or hepatic receptors that relay messages to the brain via the afferent vagus nerve. As a group they provide a number of leads for potential drug development.
Collapse
Affiliation(s)
- G A Bray
- Pennington Biomedical Research Center, Louisiana State University, Baton Rouge 70808, USA.
| |
Collapse
|
13
|
Lin L, Bray G, York DA. Enterostatin suppresses food intake in rats after near-celiac and intracarotid arterial injection. Am J Physiol Regul Integr Comp Physiol 2000; 278:R1346-51. [PMID: 10801306 DOI: 10.1152/ajpregu.2000.278.5.r1346] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Enterostatin (Ent) selectively suppresses the intake of dietary fat after peripheral and central administration. To further investigate the site of action of Ent, we compared the feeding responses to Ent injected intra-arterially near the celiac artery, into the carotid artery, or intravenously in rats adapted to a high-fat diet. After near-celiac arterial injection there was an immediate dose-dependent (0.05-13.5 nmol) inhibition of food intake occurring within 5 min in overnight-fasted rats that lasted up to 20 min. Carotid arterial Ent had a similar, immediate dose-related response, and the inhibitory effect was long lasting. The response to intravenous Ent was only evident at the highest dose (13.5 nmol) and was delayed for at least 120 min. Pretreatment with capsaicin, which causes degeneration of vagal sensory neurons, abolished the inhibitory responses to near-celiac Ent but not to intravenous or intracarotid Ent. These results provide further evidence for both a gastrointestinal site of action for peripheral Ent and a central site of action for intracarotid Ent and suggest that the delayed response to intravenous Ent may reflect either binding or slow uptake of this peptide into the central nervous system.
Collapse
Affiliation(s)
- L Lin
- Pennington Biomedical Research Center, Louisiana State University, Baton Rouge 70808, Louisiana, USA
| | | | | |
Collapse
|
14
|
Prasad A, Richards RJ, Svec F, Porter JR, Prasad C. Dehydroepiandrosterone-mediated decrease in caloric intake by obese Zucker rats is not due to changes in serum entrostatin-like immunoreactivity. Physiol Behav 2000; 68:341-5. [PMID: 10716543 DOI: 10.1016/s0031-9384(99)00185-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
To understand the mechanism(s) of appetite modulation by DHEA, we have undertaken a series of studies to examine the effects of DHEA on neurotransmitters and neuropeptides known to affect appetitive behavior. Here, we report the effect of DHEA on serum enterostatin-VPDPR or E, a pentapeptide known to cause selective diminution in fat intake. Four-week-old lean (fa/+) and obese (fa/fa) Zucker rats were divided into control and treatment groups. DHEA-treated groups received powdered chow containing 0.6% DHEA ad lib for 16 weeks. Another group of obese rats was pair fed to match the intake of the obese DHEA-treated rats. At the end of this period, trunk blood was collected from fasted rats for assay of E-like immunoreactivity (E-LI) by ELISA. DHEA treatment caused a significant diminution in circulating E-LI in both lean (control: 2030 +/- 226; treated: 752 +/- 145 ng/mL; n = 10, p < 0.0001) and obese (control: 2489 +/- 391, n = 6; treated: 1123 +/- 185 ng/mL, n = 7; p = 0.0003) rats. Because DHEA treatment decreases caloric intake and body weight, we examined the effect of caloric intake and body weight on E-LI levels. Serum ELI levels were lower in the obese DHEA-treated group compared to that of obese pair fed (pair fed: 1589 +/- 313, n = 6; DHEA: 1123 +/- 185 ng/mL, n = 7), but the differences were statistically insignificant (p = 0.185). Also, both weight-matched lean and obese control rats had significantly (p < 0.008) higher E-LI than their DHEA-treated counterparts. To examine whether the decrease in serum E-LI following DHEA treatment could be due to increased peptide metabolism, the rate of disappearance of endogenous E-LI from serum (obese control and DHEA-treated) at 37 degrees C was evaluated. The results show an attenuation of peptide metabolism in serum from DHEA-treated rats, a finding contrary to our expectations. In summary, DHEA treatment lowers serum E-LI levels both in lean and obese Zucker rats. This decrement in peptide level is not secondary to changes in body weight or caloric intake due to DHEA, or due to altered serum peptide metabolism. Although DHEA appears to be a potent modulator of E-LI levels, the relationship between DHEA and E-LI in relation to appetitive behavior remains to be clarified.
Collapse
Affiliation(s)
- A Prasad
- Department of Medicine, Louisiana State University Medical Center, New Orleans 70112, USA
| | | | | | | | | |
Collapse
|
15
|
Affiliation(s)
- G A Bray
- Louisiana State University, Pennington Biomedical Research Center, Baton Rouge 70808-4124, USA
| | | |
Collapse
|
16
|
Abstract
Procolipase is secreted as a protein consisting of 101 amino acids. In the intestinal lumen, procolipase is activated by trypsin and cleaves to form the active colipase and the pentapeptide from the amino terminus. This pentapeptide is called enterostatin. Pancreatic procolipase synthesis is stimulated by a high-fat diet. A large body of evidence has been gathered in the past decade demonstrating the role of enterostatin in the inhibition of food intake; in particular, fat intake. This aspect of enterostatin will be discussed in this review. Other functions of enterostatin such as the inhibition of insulin secretion, will not. Apolipoprotein AIV is a protein synthesized by the human intestine. Similar to procolipase, the synthesis and secretion of apo AIV are also stimulated by fat absorption. In 1992, Fujimoto et al. first demonstrated that apo AIV is a satiety signal secreted by the small intestine following the ingestion of a lipid meal. Subsequently, this initial observation was followed by a number of studies supporting apo AIV's role in the inhibition of food intake. This review will discuss the role of apo AIV in inhibiting food intake.
Collapse
Affiliation(s)
- M Liu
- Department of Pathology, University of Cincinnati, Cincinnati, OH, 45241, USA
| | | | | |
Collapse
|
17
|
Prasad C, Debata C, McGregor JU. Hormones in Foods: Presence of Enterostatin-Like Immunoreactivities in Bovine Milk. Nutr Neurosci 1999; 2:147-54. [PMID: 27415149 DOI: 10.1080/1028415x.1999.11747273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Enterostatins, pentapeptides (Val-Pro-Asp-Pro-Arg [VPDPR], Val-Pro-Gly-Pro-Arg, Ala-Pro-Gly-Pro- Arg [APGPR], and others) derived from the amino terminus of procolipase, are endogenous to a variety of tissues and body fluids including brain, gut, blood, cerebrospinal fluid, and urine. The administration of exogenous peptides has been shown to elicit a variety of biologic activities, including a decrease in dietary fat preference and pancreatic insulin secretion. Since milk is a rich source of a variety of bioactive substances, especially peptides, we investigated the presence of enterostatin-like immunoreactivity in bovine milk. We measured enterostatins-APGPR and VPDPR-in milk from a herd of 19 cows randomly selected from the Louisiana State University Department of Dairy Science Research Herd in Baton Rouge; the results of this study show a mean peptide concentration in raw milk of 33.7 ± 2.9 ng/ml for APGPR and of 104.5 ± 16.3 ng/ml for VPDPR. A further chromatographic characterization of the nature of APGPR- and VPDPR-like immunoreactivities suggested the endogenous peptides share a common epitope with APGPR or VPDPR but are not APGPR or VPDPR. Unlike APGPR or VPDPR, the endogenous peptides were heat-labile and therefore their values were much lower in pasteurized milk.
Collapse
Affiliation(s)
- C Prasad
- a Section of Endocrinology, Obesity Research Program, Department of Medicine , LSU Medical Center , 1542 Tulane Avenue, New Orleans , LA 70112 , USA
| | - C Debata
- a Section of Endocrinology, Obesity Research Program, Department of Medicine , LSU Medical Center , 1542 Tulane Avenue, New Orleans , LA 70112 , USA
| | - J U McGregor
- b Department of Dairy Science , Louisiana State University , Baton Rouge , LA 70803 , USA
| |
Collapse
|
18
|
Imamura M, Debata C, Prasad C. On the nature and distribution of enterostatin (Val-Asp-Pro-Asp-Arg)-like immunoreactivity in rat plasma. Peptides 1999; 20:133-9. [PMID: 10098634 DOI: 10.1016/s0196-9781(98)00138-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Enterostatins, pentapeptides represented at the amino-terminus of the procolipase molecule, are derived following tryptic cleavage of the procolipase molecule in the lumen of the gut. Val-Pro-Asp-Pro-Arg or VPDPR is one such enterostatin. Despite pharmacologic studies suggesting a role for VPDPR in appetite regulation and insulin secretion, the function of this endogenous peptide has been impossible to discern due to the lack of a suitable assay. Using polyclonal antibodies raised against VPDPR and different chromatographic methods, we examined the nature and distribution of enterostatin-like immunoreactivity in rat plasma. The results reported here show for the first time the presence of VPDPR-like immunoreactivity in rat plasma. Further characterization of the plasma VPDPR-like immunoreactivity revealed that a) it is not due to APGPR, VPGPR, or VPDPR but to another peptide similar to VPDPR, and b) plasma VPDPR-like immunoreactivity may circulate bound to large carrier proteins.
Collapse
Affiliation(s)
- M Imamura
- Department of Medicine, Louisiana State University Medical Center, New Orleans 70112, USA
| | | | | |
Collapse
|
19
|
Rippe C, Rippe B, Erlanson-Albertsson C. Capillary diffusion capacity and tissue distribution of pancreatic procolipase in rat. THE AMERICAN JOURNAL OF PHYSIOLOGY 1998; 275:G1179-84. [PMID: 9815049 DOI: 10.1152/ajpgi.1998.275.5.g1179] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
The permeability-surface area product of procolipase and its apparent distribution volume in rat tissues were assessed using a tissue uptake technique. Procolipase was investigated together with 51Cr-EDTA, used as an inert extracellular marker, and 131I-albumin, used as a plasma volume marker. The tissue uptake of procolipase seemed to occur by passive transport in most of the organs studied, such as in muscle, liver, lung, adipose tissue, adrenal glands, colon, and skin. However, throughout the gastrointestinal tract, except in the colon, there was a high uptake of procolipase, greatly exceeding that of 51Cr-EDTA. This was especially evident in the stomach, in which the procolipase uptake was nonsaturable within the experimental period. Also, in the central nervous system (CNS), there was evidence of specific, possibly carrier-mediated, transport. These results suggest that procolipase may have specific, conceivably receptor-mediated, transport pathways across the microvascular endothelium in the stomach, pancreas, duodenum, ileum, and the CNS.
Collapse
Affiliation(s)
- C Rippe
- Section for Molecular Signaling, Departments of Cell and Molecular Biology, University of Lund, S-221 00 Lund, Sweden
| | | | | |
Collapse
|
20
|
Imamura M, Sumar N, Hermon-Taylor J, Robertson HJ, Prasad C. Distribution and characterization of enterostatin-like immunoreactivity in human cerebrospinal fluid. Peptides 1998; 19:1385-91. [PMID: 9809653 DOI: 10.1016/s0196-9781(98)00077-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Enterostatins belong to a family of peptides (e.g., Val-Pro-Asp-Pro-Arg, VPDPR; Ala-Pro-Gly-Pro-Arg, APGPR; and Val-Pro-Gly-Pro-Arg, VPGPR) derived from the tryptic cleavage of amino-terminal pentapeptide from procolipase. Pharmacologic studies have suggested a role for these peptides in appetite regulation and insulin secretion. Studies into the distribution of enterostatins or the role of endogenous peptides have not been possible until now due to the lack of a suitable method for assay. Using two polyclonal antibodies raised against VPDPR and APGPR and different chromatographic methods, we have examined the nature and distribution of enterostatin-like immunoreactivity in human cerebrospinal fluid. The results reported here show for the first time the presence of enterostatin-like immunoreactivity in the human cerebrospinal fluid. Further characterization of cerebrospinal fluid enterostatin-like immunoreactivity revealed that it is not due to APGPR, VPGPR, or VPDPR but to another peptide similar to VPDPR.
Collapse
Affiliation(s)
- M Imamura
- Department of Medicine, Louisiana State University Medical Center, New Orleans 70112, USA
| | | | | | | | | |
Collapse
|
21
|
Abstract
A high fat intake, together with an inability to match lipid oxidation to fat intake, has been found to be correlated with obesity in humans. This review describes our current understanding of enterostatin, a peptide that selectively reduces fat intake. Enterostatin is formed in the intestine by the cleavage of secreted pancreatic procolipase, the remaining colipase serving as an obligatory cofactor for pancreatic lipase during fat digestion. Enterostatin is also produced in the gastric mucosa and the mucosal epithelia of the small intestine. Procolipase gene transcription and enterostatin release into the gastrointestinal lumen are increased by high-fat diets. After feeding, enterostatin appears in the lymph and circulation. Enterostatin will selectively inhibit fat intake during normal feeding and in experimental paradigms that involve dietary choice. Its anorectic effect has been demonstrated in a number of species. Both peripheral and central sites of action have been proposed. The peripheral mechanism involves an afferent vagal signaling pathway to hypothalamic centers. The central responses are mediated through a pathway that includes both serotonergic and opioidergic components. Chronically, enterostatin reduces fat intake, bodyweight, and body fat. This response may involve multiple metabolic effects of enterostatin, which include a reduction of insulin secretion, an increase in sympathetic drive to brown adipose tissue, and the stimulation of adrenal corticosteroid secretion. A possible pathophysiological role is suggested by studies that have linked low enterostatin production and/or responsiveness to strains of rat that become obese and prefer dietary fat. Humans with obesity also exhibit a lower secretion of pancreatic procolipase after a test meal, compared with persons of normal weight.
Collapse
|
22
|
Abstract
The effects of central and peripheral administration of enterostatin (ENT) on food intake and gastric emptying of a non-nutrient liquid meal have been studied in rats. Intraperitoneal and intragastric administration of ENT at a dose of 120 nmol suppressed the intake of a high-fat diet but failed to inhibit gastric emptying in Sprague-Dawley (SD) rats. Intracerebroventricular (i.c.v.) ENT (1 nmol) reduced intake of a high-fate diet in Osborne-Mendel (OM) and SD rats but not in S5B/Pl rats, whereas it decreased gastric emptying in S5B/P1 and SD rats but not in OM rats. The data suggest that although central ENT may reduce gastric emptying rate, this effect is not related to the inhibitory effect of ENT on food intake.
Collapse
Affiliation(s)
- L Lin
- Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA
| | | |
Collapse
|